Goldman Sachs tips ResMed share price to race higher

The ResMed Inc. (ASX:RMD) share price could race higher after Goldman Sachs lifted its price target…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc. (ASX: RMD) share price was one of the best performers on the ASX 200 last week.

During the period the sleep treatment-focused medical device company's shares recorded a 7% weekly gain.

Why did ResMed's shares race higher?

The driver of this impressive gain was the release of a very strong quarterly update.

That update saw ResMed post first quarter revenue of US$681.1 million, up 16.1% on the prior corresponding period.

Pleasingly, thanks to further improvements in its margins, net operating profit increased at an even quicker rate of 19%. This led to the company posting diluted earnings per share of 93 U.S. cents.

Both its revenue and earnings smashed the market's expectations, leading to investors scrambling to pick up shares.

Is it too late to invest?

I don't believe it is too late to invest. I still see a lot of value in its shares for investors focused on making a buy and hold investment.

This view is echoed by analysts at Goldman Sachs. A note out of the investment bank reveals that they have retained their buy rating and lifted the price target on its shares to $23.20. This price target implies potential upside of more than 10% over the next 12 months.

Goldman was impressed with ResMed's performance in the first quarter, particularly from its masks business. It said: "The greater share of today's +8% beat is driven by masks (+19% in each of US and RoW is the strongest performance since disclosed separately), and 1Q20 is the 9th consecutive quarter of double-digit EBIT growth (+22%)."

And while the broker expects this growth to moderate, it still sees solid growth ahead.

"Whilst these rates are unlikely sustainable, we expect masks to continue to deliver low-teens growth (GSe: +13%), driven by effective portfolio management and successful re-supply programs," it added.

The broker also spoke positively about its valuation. Pointing out that although its shares have hit an all-time high, they are still trading below the healthcare peer group of Cochlear Limited (ASX: COH), CSL Limited (ASX: CSL), and Fisher & Paykel Healthcare Corp Ltd (ASX: FPH).

Overall, I think Goldman makes some great points and suspect its shares may be heading higher again today.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Falling yellow arrow with descending wooden bars with the percentage sign written on them.
Share Market News

How much cash will the average mortgage holder save if the RBA cuts interest rates tomorrow?

And how to best redeploy those funds?

Read more »

most shorted shares webjet
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

A man in a business suit peers through binoculars as two businesswomen stand beside him looking straight ahead at the camera.
Share Market News

Trump's 9 July tariff deadline looms: 3 ASX 200 companies to watch

It could shape up to be a big week on the tariff front.

Read more »

Business meeting to discuss buy now pay later platform
Broker Notes

Macquarie tips substantial upside for Steadfast shares

Steadfast is a high-quality business at an attractive valuation, according to the broker.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Market News

5 things to watch on the ASX 200 on Monday

Here's what to expect on the local market on Monday.

Read more »

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Magnifying glass in front of an open newspaper with paper houses.
Share Market News

How did ASX REITs vs. residential property investment perform in FY25?

We review the share price growth of the largest ASX REITs vs. residential property investment in FY25.

Read more »

A man and woman sit next to each other looking at each other and feeling excited and surprised after reading good news about their shares on a laptop.
Broker Notes

These ASX 200 shares could rise 55% to 65%

Analysts think these shares are dirt cheap at current levels.

Read more »